Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Spravato vs Ketamine Troches: What the Effectiveness Evidence Actually Shows
If you are weighing Spravato (esketamine nasal spray) against ketamine troches for treatment-resistant depression or another mood condition, the first thing to understand is that these are not the same drug delivered in different packaging. Spravato contains esketamine, a specific molecular mirror image of ketamine, while compounded troches contain racemic ketamine, a slightly different chemical mix. Both work on NMDA receptors, but their regulatory histories, delivery settings, and clinical evidence bases differ considerably.
This guide walks through what researchers and regulators currently know about effectiveness, how each route is administered, and the practical questions that matter most when you are trying to figure out which option to ask your clinician about. It is not a substitute for a personalized medical evaluation, your history, diagnosis, and access situation all shape which path makes sense for you.
The Core Regulatory Difference
Spravato received FDA approval in 2019 for treatment-resistant depression (TRD) in adults who have not responded to at least two oral antidepressants, and in 2020 for major depressive disorder with acute suicidal ideation or behavior (MDSI). That approval came with a Risk Evaluation and Mitigation Strategy (REMS), which means it can only be administered in certified healthcare settings with at least two hours of post-dose monitoring. You cannot take Spravato home.
Ketamine troches, compounded sublingual or buccal lozenges, occupy a different regulatory category. Compounded ketamine is not FDA-approved for any psychiatric indication. Prescribers use it off-label under their clinical judgment, and most programs allow patients to dissolve troches at home after an initial supervised session. The DEA classifies ketamine as a Schedule III controlled substance, which affects how it is prescribed, dispensed, and stored.
Neither route being "FDA-approved for depression" in the same sense applies here: Spravato is FDA-approved (esketamine, in-clinic, under REMS), and compounded ketamine troches are legally prescribed off-label by licensed clinicians. Understanding this distinction helps set realistic expectations when comparing what the evidence does and does not show.
Compare troche options
Compare troches with other ketamine routes and safety considerations.
Compare optionsAbout the Evidence Gap
Most clinical trial data on esketamine comes from the Spravato REMS program and manufacturer-sponsored studies. Large-scale randomized trials comparing compounded ketamine troches directly against Spravato do not yet exist. Clinicians often draw on IV ketamine research, observational studies of sublingual ketamine, and the esketamine trial record to inform troche prescribing, which is a reasonable but imperfect extrapolation. Discuss what the evidence does and does not cover with your prescriber before making a treatment decision.
What Clinical Research Says About Spravato's Effectiveness
The pivotal trials for Spravato showed statistically significant reductions in depression symptoms compared to placebo in patients with TRD, as measured by the Montgomery, Åsberg Depression Rating Scale (MADRS). A 2019 study published in JAMA Psychiatry reported that esketamine plus a newly initiated oral antidepressant produced faster symptom reduction than placebo plus antidepressant in patients with MDD who had active suicidal ideation.
However, the results were not uniformly robust across all trial phases. Some studies showed the advantage over placebo narrowing at later time points, and remission rates, full resolution of symptoms, remained modest. The FDA reviewers noted these nuances in their approval documents. Long-term maintenance data exist but are less extensive than for established antidepressants.
Effect sizes in TRD trials are generally meaningful but not dramatic: many patients see improvement, fewer reach full remission, and some do not respond. Discontinuation rates in clinical practice vary, and researchers have studied how delivery format affects whether people stay with ketamine-based treatment over time, a topic covered in more depth in our guide on ketamine discontinuation rates and delivery format.
What Research Suggests About Ketamine Troche Effectiveness
The evidence base for compounded ketamine troches is smaller and more observational than the Spravato trial record. Most published data on sublingual and buccal ketamine comes from case series, retrospective chart reviews, and smaller prospective studies rather than large placebo-controlled trials. That is partly because compounded products cannot be patented, which limits pharmaceutical industry investment in formal trials.
What those studies generally show: sublingual ketamine can produce antidepressant effects, though onset and magnitude vary considerably by individual. Bioavailability through the sublingual and buccal mucosa is estimated at roughly 25-50% of the administered dose, lower than IV ketamine and in a different range than intranasal esketamine. That variability matters: how long you hold the troche, how much saliva you produce, and the specific compounding formulation can all affect how much drug reaches your bloodstream. Our article on intranasal esketamine safety, efficacy, and how troches compare goes deeper on these bioavailability differences.
Researchers have also noted that the at-home setting of troche use changes the experience meaningfully, some patients find the flexibility helpful for sustaining treatment, while others find that the lack of structured clinical support reduces accountability. For a look at patient-level outcome patterns, see our overview of subcutaneous ketamine vs troches patient outcomes, which touches on how setting shapes response.
Spravato vs Ketamine Troches: Key Differences at a Glance
| Feature | Spravato (Esketamine) | Ketamine Troches |
|---|---|---|
| Active compound | Esketamine (S-enantiomer) | Racemic ketamine (R+S mixture) |
| FDA approval status | FDA-approved for TRD and MDSI under REMS | Compounded, prescribed off-label; not FDA-approved for depression |
| Administration setting | Certified clinic only; 2-hour post-dose monitoring required | Typically at home after initial supervised session |
| Route | Intranasal spray, self-administered in clinic | Sublingual or buccal lozenge dissolved under tongue or in cheek |
| Bioavailability estimate | Approximately 48% intranasal absorption per manufacturer data | Estimated 25-50% sublingual/buccal; varies by technique and formulation |
| Insurance coverage | Often covered for qualifying diagnoses; prior authorization common | Rarely covered; usually out-of-pocket |
| Head-to-head trial data | Not directly compared against troches in published RCTs | Not directly compared against Spravato in published RCTs |
| Flexibility | Fixed clinic schedule; less flexible | Dosing schedule set by prescriber; taken at home |
Why No Head-to-Head Trial Exists, and What That Means for You
The absence of a large randomized trial directly comparing Spravato to ketamine troches is not an accident. Running such a trial would require a neutral funder with no stake in either product, agreement on outcome measures, and resolution of the fundamental methodological challenge: you cannot easily blind patients to whether they are dissolving a lozenge at home or sitting in a clinic for two hours. This means clinicians and patients have to synthesize evidence across separate research streams rather than relying on a single definitive comparison.
In practice, that means your prescriber will weigh factors like your diagnosis, prior treatment history, available access, insurance situation, and personal tolerance for clinical monitoring when recommending one route over another. Neither "more FDA-approved" nor "more flexible" automatically means more effective for any individual patient.
Practical Factors That Affect Which Route Fits
Diagnosis and Eligibility
Spravato's REMS approval is specifically for TRD (failed 2+ antidepressants) or MDSI. Troches may be prescribed for a broader range of conditions at a clinician's discretion, including off-label uses outside that diagnosis set.
Monitoring Requirements
Spravato requires in-clinic administration with post-dose observation for at least two hours due to dissociation and sedation risks. Troche protocols vary by prescriber but often involve a supervised first session and then home use with aftercare guidelines.
Cost and Insurance
Spravato is sometimes covered by insurance for qualifying patients, though prior authorization and step-therapy requirements are common. Compounded troches are typically paid out-of-pocket. See our guide on how much ketamine troches cost for current range estimates.
At-Home Access
Troches offer flexibility that appeals to patients with transportation barriers, demanding work schedules, or caregiving responsibilities. That same flexibility shifts more responsibility for preparation, mindset, and aftercare to the patient.
Technique Sensitivity
Troche effectiveness is partly technique-dependent: where you hold the lozenge, how long before swallowing the remaining material, and what you eat or drink beforehand can all affect absorption. Spravato dosing in clinic removes some of these variables.
Access Gaps in Underserved Areas
Certified Spravato clinics are unevenly distributed geographically. For patients in rural or underserved areas, compounded troches prescribed through telehealth may represent a more accessible starting point, a gap explored in our article on esketamine TRD access gaps and ketamine troches.
Onset, Duration, and the Experience of Each Route
Both Spravato and ketamine troches typically produce dissociative effects, perceptual changes, altered sense of time, or a feeling of detachment, during or shortly after administration. The character and timing of that experience differ between routes.
With Spravato nasal spray, onset usually begins within minutes of administration, peaks around 20-40 minutes, and largely subsides within two hours, which is why the REMS requires that monitoring window. The nasal route delivers drug directly to systemic circulation relatively quickly.
With sublingual troches, onset is slower and more variable, often 15-30 minutes to initial effects, with the peak experience typically around 45-75 minutes depending on the dose and individual absorption. The troche's extended dissolving time (usually 15-20 minutes of holding the lozenge) means the drug enters the bloodstream gradually. Our detailed guide to ketamine troche onset, peak, and duration timeline covers this in depth, including how to set up your environment at home for the session.
Neither route is inherently more or less intense for every person, dose, individual neurochemistry, and set and setting all interact. What differs is how much of that experience happens under clinical supervision versus at home.
Safety Considerations Specific to Each Route
Both Spravato and ketamine troches carry risks that include dissociation, elevated blood pressure, nausea, dizziness, and in some cases psychological distress during or after a session. The FDA's Spravato labeling includes a boxed warning about sedation and dissociation, the two-hour REMS monitoring requirement, and a note about potential for misuse and abuse given ketamine's Schedule III status.
For troches used at home, the safety framework shifts to the patient and their support network. Reputable prescribers establish protocols that include: not driving or operating machinery for a defined period after dosing, having a responsible adult present or reachable, knowing what constitutes a reason to seek emergency care, and having a plan if psychological distress does not resolve after the session window.
If you or someone you know is experiencing a mental health emergency or suicidal crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or go to your nearest emergency room. Ketamine treatment, in any form, does not replace emergency mental health care.
Questions to Bring to Your Clinician When Comparing These Options
Do I meet the diagnostic criteria for Spravato's FDA-approved indications?
Spravato is approved for TRD (two or more failed antidepressant trials in the current episode) and MDSI. If your history does not fit those categories, your clinician may lean toward an off-label option like troches, or may recommend a different approach entirely.
What does my insurance actually cover, and what are the real out-of-pocket costs for each?
Get specifics before assuming Spravato is cheaper because it is FDA-approved. Prior authorization requirements, step therapy, and clinic facility fees can shift the math. Ask your prescriber's office to check benefits before your first session.
Can I realistically attend a clinic twice a week for the initial Spravato induction phase?
The standard Spravato induction involves twice-weekly sessions for four weeks, then weekly or every-two-weeks maintenance. If that schedule is not feasible given work, transportation, or caregiving, troches' at-home flexibility may be a relevant factor.
What does my prescriber's troche protocol look like for the at-home setting?
Ask specifically: How is my first session supervised? What aftercare instructions apply? What symptoms should prompt me to contact the clinic or seek emergency care? A protocol with clear answers suggests a thoughtful program.
Are there reasons my specific history makes one route preferable?
Cardiovascular history, substance use history, certain psychiatric diagnoses, and medication interactions can all affect which route a clinician recommends. This is not a decision that should be made on general effectiveness data alone.
What Patients Often Report: Qualitative Differences
Beyond clinical trial metrics, patients and clinicians have noted some consistent qualitative differences in how the two routes are experienced in practice, though these are not based on randomized research and vary widely by individual.
Patients using Spravato in clinic often describe the structured, monitored setting as reassuring, particularly if they have anxiety about the dissociative experience. Having a clinical team present can feel supportive. Some find the twice-weekly schedule during induction disruptive, and a minority report nasal discomfort from the spray.
Patients using troches at home frequently cite schedule flexibility and privacy as positives. Being in a familiar environment can support a more relaxed mindset. The extended dissolving time and slight bitterness or numbing sensation of the lozenge are commonly noted, our page on what to do when your troche is not dissolving addresses one of the most common practical questions that comes up in home use.
Neither experience is universally better. The right fit depends on what helps you feel safe, supported, and consistent enough to complete a full course of treatment.
Frequently Asked Questions
There is no published head-to-head randomized trial comparing Spravato directly to ketamine troches. Spravato has a larger formal clinical trial record because it went through FDA approval for specific diagnoses. Compounded ketamine troches have a smaller, more observational evidence base. Neither has been proven definitively superior to the other for depression in a direct comparison. Your clinician will weigh your individual history, diagnosis, and access situation rather than relying on a single effectiveness ranking.
Spravato must be administered in a certified healthcare setting with at least two hours of post-dose monitoring, as required by its FDA REMS program. It cannot legally be taken home. Ketamine troches, when prescribed by a licensed clinician, are commonly used at home after an initial supervised session, the specific protocol varies by prescriber. If at-home flexibility is important to your situation, discuss troche protocols with your clinician and ask what supervision and aftercare requirements apply.
They are closely related but not identical. Ketamine is a racemic mixture of two mirror-image molecules: S-ketamine (esketamine) and R-ketamine. Spravato contains only the S-enantiomer. Compounded ketamine troches typically contain the full racemic mixture. The two forms have somewhat different receptor binding profiles, and researchers are still studying whether those differences translate to meaningful clinical outcome differences. Your prescriber can explain how this distinction applies to your situation.
Spravato is sometimes covered by insurance for patients who meet its FDA-approved indications (TRD or MDSI), though prior authorization, step therapy requirements, and facility fees mean coverage varies significantly by plan. Compounded ketamine troches are almost never covered by insurance and are typically paid out of pocket. Costs vary by compounding pharmacy, dose, and frequency. Our guide on how much ketamine troches cost covers typical price ranges.
Spravato typically produces effects within minutes of nasal administration, peaking around 20-40 minutes. Ketamine troches generally have a slower onset, often 15-30 minutes, because the drug is absorbed gradually through the mucous membranes as the lozenge dissolves. Onset can vary based on technique, how long you hold the troche, and individual absorption differences. See our guide on ketamine troche onset, peak, and duration for a more detailed timeline.
Certified Spravato clinics are not evenly distributed across all regions. Patients in rural or underserved areas may have limited access to in-clinic esketamine. In some cases, clinicians prescribe compounded ketamine troches via telehealth as a more geographically accessible alternative. Our article on esketamine TRD access gaps and ketamine troches covers this landscape in more detail. Discuss your options with a licensed prescriber who can evaluate your specific situation.
Ketamine troches are typically prescribed with a protocol that includes supervised initial sessions and clear at-home guidelines, not a fully unmonitored free-for-all. Reputable prescribers provide instructions about what to avoid before and after dosing, who should be available during a session, what symptoms warrant contacting the clinic, and when to seek emergency care. Dissociation, elevated blood pressure, and psychological distress are possible effects. Following your prescriber's protocol carefully and having a support person available is important for home use.
Clinicians sometimes prescribe compounded ketamine off-label for anxiety disorders, PTSD, chronic pain, and other conditions, in addition to depression. This is distinct from Spravato, which is FDA-approved only for TRD and MDSI. Off-label use means the prescriber is using their clinical judgment beyond the formal approved indication. The evidence base for troches in non-depression conditions is generally thinner, and what is appropriate depends heavily on your individual history and a qualified clinician's evaluation.
Compare Troches With Other Ketamine Routes
Keep learning with related guides before making treatment decisions. We cover how sublingual troches compare to IV infusions, intramuscular injections, and more.
Share
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.